 |
PDBsum entry 1nvq
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
The complex structure of checkpoint kinase chk1/ucn-01
|
|
Structure:
|
 |
Serine/threonine-protein kinase chk1. Chain: a. Fragment: chk1kd (residues 1-289). Engineered: yes. Peptide asvsa. Chain: b. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: unidentified baculovirus. Expression_system_taxid: 10469. Synthetic: yes
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.206
|
R-free:
|
0.234
|
|
|
Authors:
|
 |
B.Zhao,M.J.Bower,P.J.Mcdevitt,H.Zhao,S.T.Davis,K.O.Johanson, S.M.Green,N.O.Concha,B.B.Zhou
|
Key ref:
|
 |
B.Zhao
et al.
(2002).
Structural basis for Chk1 inhibition by UCN-01.
J Biol Chem,
277,
46609-46615.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
04-Feb-03
|
Release date:
|
08-Apr-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
O14757
(CHK1_HUMAN) -
Serine/threonine-protein kinase Chk1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
476 a.a.
264 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
277:46609-46615
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for Chk1 inhibition by UCN-01.
|
|
B.Zhao,
M.J.Bower,
P.J.McDevitt,
H.Zhao,
S.T.Davis,
K.O.Johanson,
S.M.Green,
N.O.Concha,
B.B.Zhou.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Chk1 is a serine-threonine kinase that plays an important role in the DNA damage
response, including G(2)/M cell cycle control. UCN-01 (7-hydroxystaurosporine),
currently in clinical trials, has recently been shown to be a potent Chk1
inhibitor that abrogates the G(2)/M checkpoint induced by DNA-damaging agents.
To understand the structural basis of Chk1 inhibition by UCN-01, we determined
the crystal structure of the Chk1 kinase domain in complex with UCN-01. Chk1
structures with staurosporine and its analog SB-218078 were also determined. All
three compounds bind in the ATP-binding pocket of Chk1, producing only slight
changes in the protein conformation. Selectivity of UCN-01 toward Chk1 over
cyclin-dependent kinases can be explained by the presence of a hydroxyl group in
the lactam moiety interacting with the ATP-binding pocket. Hydrophobic
interactions and hydrogen-bonding interactions were observed in the structures
between UCN-01 and the Chk1 kinase domain. The high structural complementarity
of these interactions is consistent with the potency and selectivity of UCN-01.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. A ribbon diagram of the Chk1 kinase domain in
complex with UCN-01. The N-terminal domain is in green, the
C-terminal domain is in yellow, and the activation loop is in
magenta. Elements of secondary structure are numbered from the N
to the C termini accordingly. UCN-01 is shown in a
ball-and-stick presentation: red for oxygen atoms, blue for
nitrogen, and yellow for carbon. All figures were created with
the computer programs MolScript (25) and BobScript (26).
|
 |
Figure 5.
Fig. 5. The solvent-accessible surface of the bound
conformation of UCN-01 (purple) is shown with the
solvent-accessible surface of Chk1 (green mesh) in the
Chk1·UCN-01 complex. The shape complementarity between
this rigid inhibitor and the binding site is very high, and the
large amount of non-polar buried surface area in the complex
provides the energy for a very strong interaction.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2002,
277,
46609-46615)
copyright 2002.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.M.Connell,
A.Shibata,
L.A.Tookman,
K.M.Archibald,
M.B.Flak,
K.J.Pirlo,
M.Lockley,
S.P.Wheatley,
and
I.A.McNeish
(2011).
Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
|
| |
J Clin Invest,
121,
1283-1297.
|
 |
|
|
|
|
 |
E.Gallmeier,
P.C.Hermann,
M.T.Mueller,
J.G.Machado,
A.Ziesch,
E.N.De Toni,
A.Palagyi,
C.Eisen,
J.W.Ellwart,
J.Rivera,
B.Rubio-Viqueira,
M.Hidalgo,
F.Bunz,
B.Göke,
and
C.Heeschen
(2011).
Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.
|
| |
Stem Cells,
29,
418-429.
|
 |
|
|
|
|
 |
P.Dobeš,
J.Fanfrlík,
J.Rezáč,
M.Otyepka,
and
P.Hobza
(2011).
Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.
|
| |
J Comput Aided Mol Des,
25,
223-235.
|
 |
|
|
|
|
 |
W.Ye,
and
S.W.Blain
(2011).
Chk1 has an essential role in the survival of differentiated cortical neurons in the absence of DNA damage.
|
| |
Apoptosis,
16,
449-459.
|
 |
|
|
|
|
 |
E.Despras,
F.Daboussi,
O.Hyrien,
K.Marheineke,
and
P.L.Kannouche
(2010).
ATR/Chk1 pathway is essential for resumption of DNA synthesis and cell survival in UV-irradiated XP variant cells.
|
| |
Hum Mol Genet,
19,
1690-1701.
|
 |
|
|
|
|
 |
O.A.Gani,
and
R.A.Engh
(2010).
Protein kinase inhibition of clinically important staurosporine analogues.
|
| |
Nat Prod Rep,
27,
489-498.
|
 |
|
|
|
|
 |
X.M.Chen,
T.Lu,
S.Lu,
H.F.Li,
H.L.Yuan,
T.Ran,
H.C.Liu,
and
Y.D.Chen
(2010).
Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.
|
| |
J Mol Model,
16,
1195-1204.
|
 |
|
|
|
|
 |
C.D.Shomin,
S.C.Meyer,
and
I.Ghosh
(2009).
Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.
|
| |
Bioorg Med Chem,
17,
6196-6202.
|
 |
|
|
|
|
 |
D.Tanramluk,
A.Schreyer,
W.R.Pitt,
and
T.L.Blundell
(2009).
On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine.
|
| |
Chem Biol Drug Des,
74,
16-24.
|
 |
|
|
|
|
 |
S.Deslandes,
S.Chassaing,
and
E.Delfourne
(2009).
Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.
|
| |
Mar Drugs,
7,
754-786.
|
 |
|
|
|
|
 |
S.J.Lee,
M.H.Cobb,
and
E.J.Goldsmith
(2009).
Crystal structure of domain-swapped STE20 OSR1 kinase domain.
|
| |
Protein Sci,
18,
304-313.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Sugimoto,
M.Sasaki,
Y.Isobe,
M.Tsutsui,
H.Suto,
J.Ando,
K.Tamayose,
M.Ando,
and
K.Oshimi
(2008).
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
|
| |
Oncogene,
27,
3091-3101.
|
 |
|
|
|
|
 |
T.Göhler,
I.M.Munoz,
J.Rouse,
and
J.J.Blow
(2008).
PTIP/Swift is required for efficient PCNA ubiquitination in response to DNA damage.
|
| |
DNA Repair (Amst),
7,
775-787.
|
 |
|
|
|
|
 |
D.Deckbar,
J.Birraux,
A.Krempler,
L.Tchouandong,
A.Beucher,
S.Walker,
T.Stiff,
P.Jeggo,
and
M.Löbrich
(2007).
Chromosome breakage after G2 checkpoint release.
|
| |
J Cell Biol,
176,
749-755.
|
 |
|
|
|
|
 |
G.Bunkoczi,
E.Salah,
P.Filippakopoulos,
O.Fedorov,
S.Müller,
F.Sobott,
S.A.Parker,
H.Zhang,
W.Min,
B.E.Turk,
and
S.Knapp
(2007).
Structural and functional characterization of the human protein kinase ASK1.
|
| |
Structure,
15,
1215-1226.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Al-Ali,
T.J.Ragan,
X.Gao,
and
T.K.Harris
(2007).
Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains.
|
| |
Bioconjug Chem,
18,
1294-1302.
|
 |
|
|
|
|
 |
H.C.Reinhardt,
A.S.Aslanian,
J.A.Lees,
and
M.B.Yaffe
(2007).
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
|
| |
Cancer Cell,
11,
175-189.
|
 |
|
|
|
|
 |
J.K.Horton,
D.F.Stefanick,
P.S.Kedar,
and
S.H.Wilson
(2007).
ATR signaling mediates an S-phase checkpoint after inhibition of poly(ADP-ribose) polymerase activity.
|
| |
DNA Repair (Amst),
6,
742-750.
|
 |
|
|
|
|
 |
K.L.Arrington,
and
V.Y.Dudkin
(2007).
Novel Inhibitors of Checkpoint Kinase 1.
|
| |
ChemMedChem,
2,
1571-1585.
|
 |
|
|
|
|
 |
M.Ikuta,
M.Kornienko,
N.Byrne,
J.C.Reid,
S.Mizuarai,
H.Kotani,
and
S.K.Munshi
(2007).
Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors.
|
| |
Protein Sci,
16,
2626-2635.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.Tuteja,
and
S.Mahajan
(2007).
Further Characterization of Calcineurin B-Like Protein and Its Interacting Partner CBL-Interacting Protein Kinase from Pisum sativum.
|
| |
Plant Signal Behav,
2,
358-361.
|
 |
|
|
|
|
 |
A.Krystyniak,
C.Garcia-Echeverria,
C.Prigent,
and
S.Ferrari
(2006).
Inhibition of Aurora A in response to DNA damage.
|
| |
Oncogene,
25,
338-348.
|
 |
|
|
|
|
 |
C.Sánchez,
C.Méndez,
and
J.A.Salas
(2006).
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity.
|
| |
Nat Prod Rep,
23,
1007-1045.
|
 |
|
|
|
|
 |
H.Hénon,
F.Anizon,
R.M.Golsteyn,
S.Léonce,
R.Hofmann,
B.Pfeiffer,
and
M.Prudhomme
(2006).
Synthesis and biological evaluation of new dipyrrolo[3,4-a:3,4-c]carbazole-1,3,4,6-tetraones, substituted with various saturated and unsaturated side chains via palladium catalyzed cross-coupling reactions.
|
| |
Bioorg Med Chem,
14,
3825-3834.
|
 |
|
|
|
|
 |
J.S.Chen,
S.Y.Lin,
W.L.Tso,
G.C.Yeh,
W.S.Lee,
H.Tseng,
L.C.Chen,
and
Y.S.Ho
(2006).
Checkpoint kinase 1-mediated phosphorylation of Cdc25C and bad proteins are involved in antitumor effects of loratadine-induced G2/M phase cell-cycle arrest and apoptosis.
|
| |
Mol Carcinog,
45,
461-478.
|
 |
|
|
|
|
 |
C.J.Squire,
J.M.Dickson,
I.Ivanovic,
and
E.N.Baker
(2005).
Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation.
|
| |
Structure,
13,
541-550.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Q.Cheng,
C.W.Lindsley,
G.Z.Cheng,
H.Yang,
and
S.V.Nicosia
(2005).
The Akt/PKB pathway: molecular target for cancer drug discovery.
|
| |
Oncogene,
24,
7482-7492.
|
 |
|
|
|
|
 |
M.V.Blagosklonny
(2005).
Overcoming limitations of natural anticancer drugs by combining with artificial agents.
|
| |
Trends Pharmacol Sci,
26,
77-81.
|
 |
|
|
|
|
 |
S.Barrett,
S.Bartlett,
A.Bolt,
A.Ironmonger,
C.Joce,
A.Nelson,
and
T.Woodhall
(2005).
Configurational stability of bisindolylmaleimide cyclophanes: from conformers to the first configurationally stable, atropisomeric bisindolylmaleimides.
|
| |
Chemistry,
11,
6277-6285.
|
 |
|
|
|
|
 |
Y.Lubelsky,
N.Reuven,
and
Y.Shaul
(2005).
Autorepression of rfx1 gene expression: functional conservation from yeast to humans in response to DNA replication arrest.
|
| |
Mol Cell Biol,
25,
10665-10673.
|
 |
|
|
|
|
 |
A.Eastman
(2004).
Cell cycle checkpoints and their impact on anticancer therapeutic strategies.
|
| |
J Cell Biochem,
91,
223-231.
|
 |
|
|
|
|
 |
B.B.Zhou,
and
J.Bartek
(2004).
Targeting the checkpoint kinases: chemosensitization versus chemoprotection.
|
| |
Nat Rev Cancer,
4,
216-225.
|
 |
|
|
|
|
 |
C.Swanton
(2004).
Cell-cycle targeted therapies.
|
| |
Lancet Oncol,
5,
27-36.
|
 |
|
|
|
|
 |
D.Komander,
G.S.Kular,
A.W.Schüttelkopf,
M.Deak,
K.R.Prakash,
J.Bain,
M.Elliott,
M.Garrido-Franco,
A.P.Kozikowski,
D.R.Alessi,
and
D.M.van Aalten
(2004).
Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1.
|
| |
Structure,
12,
215-226.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.C.Mack,
A.A.Jones,
M.H.Gustafsson,
D.R.Gandara,
P.H.Gumerlock,
and
Z.Goldberg
(2004).
Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.
|
| |
Radiat Res,
162,
623-634.
|
 |
|
|
|
|
 |
Y.Dai,
and
S.Grant
(2004).
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
|
| |
Curr Oncol Rep,
6,
123-130.
|
 |
|
|
|
|
 |
E.De Moliner,
N.R.Brown,
and
L.N.Johnson
(2003).
Alternative binding modes of an inhibitor to two different kinases.
|
| |
Eur J Biochem,
270,
3174-3181.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.M.Fischer,
and
A.Gianella-Borradori
(2003).
CDK inhibitors in clinical development for the treatment of cancer.
|
| |
Expert Opin Investig Drugs,
12,
955-970.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |